Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

ix month periods ended January 31, 2008, compared to $310,000 and $600,000, respectively, for the same periods last year. Margins, on percentage basis, have remained relatively stable in both the three and six month periods ended January 31, 2008, when compared to 2007.

Research & development

Research & development costs for the three and six month periods ended January 31, 2008, totaled $1,029,000 and $1,811,000, respectively, compared to $1,065,000 and $1,973,000, respectively, a year ago. In the three and six month periods ended January 31, 2008, research & development expenditures for both L-DOS47 and Topical Interferon Alpha2-b were less than in the same periods a year ago, with the majority of the lower research and development expenditures related to L-DOS47.

The reduction in research and development expenditures for L-DOS47 in the period were related to the various stages of completion associated with the multiple projects within the L-DOS47 program. Helix intends to seek approval in 2008 from the U.S. Food and Drug Administration ("FDA") for a Phase I clinical study in lung adenocarcinoma patients and, therefore, is currently advancing its L-DOS47 scale-up manufacturing program in anticipation of furnishing product for the clinical trial.

Research and development expenditures related to the Phase II trial in Sweden for ano-genital warts ("AGW") were more than offset by the reduction in costs associated with the Phase II study in Germany for women with precancerous, HPV induced low-grade cervical lesions.

The late-stage Phase II study in Germany was completed during the six month period ended January 31, 2007. Based on the positive findings, the Company is currently developing plans for a large, randomized, placebo-controlled double-blind study to evaluate the product in an expanded patient population in addition to preparatory work in anticipation of Investigational New Drug ("IND") and Clinical Trial Application ("CTA") f
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... that it has received orders for the sale of ... far in its initial sales push,being led by new ... current efforts, shall announce such sales as and,when they ... an award-winning life sciences company focused on,the monitoring and ...
... 20 AMDL, Inc. (Amex:,ADL), headquartered in ... Jilin, China, through its wholly owned subsidiary ... company that,engages in the development, manufacture and ... announced today that JPI has a,new product ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a global ... in the UBS Global Life,Sciences Conference, which is being ... On Monday, September 24, 2007 at 8:30am ET, Dr. ... give a 25-minute,presentation. A link to the live ...
Cached Biology Technology:Signalife Achieves $1.98 Million Sales Orders Thus Far 2AMDL's Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development 2Angiotech to participate in UBS Global Life Sciences Conference 2Angiotech to participate in UBS Global Life Sciences Conference 3
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... San Diego Cytori Therapeutics (NASDAQ: CYTX) announced ... from APOLLO, the Company,s European clinical trial evaluating ... with acute myocardial infarction (heart attack or AMI), ... the American College of Cardiology . The APOLLO ...
... of which are preventable via vaccines readily available in the ... of death for children in sub-Saharan Africa. ... funded by a $5.8 million grant aims to help prevent ... vaccine use and development. Funded by the Bill & Melinda ...
... the causes of the obesity epidemic in Aboriginal children ... factors that shape the Aboriginal community. A review article ... emphasizes that early childhood obesity prevention efforts should begin ... on breastfeeding initiatives and nutrition in the early childhood ...
Cached Biology News:Adipose stem cell heart attack trial data published in JACC 2$5.8 million Gates grant targets child-killing bacteria diseases in Africa 2
... volume pipetting is increasingly essential for ... DNA sequencing and other biochemical applications. ... and precision unparalleled in the industry. ... of all aspirated,and dispensed volumes , ...
... the rapid isolation of DNA from high melt ... the spin filter, centrifuge for 3 minutes, and ... is no need to melt agarose or use ... be used for buffer exchange, primer removal from ...
Request Info...
Guinea Pig Complement...
Biology Products: